title: Safety of ephedra: lessons learned.
abstract: The safe use of ephedra represents the best possible outcome of a convergence of variables, some with troubling potential outcomes. Commercially used ephedra and its products is prepared from Ephedra spp. and as such is subject to a variety of influences (including differences in species and strain; growth, harvest and storage conditions) all of which may influence the content of constituents (which may, in turn, affect the absorption, distribution, and metabolism of active constituents) and taken together, influences the net pharmacological effect. Further, as a natural substance with an easily perceived and desirable (i.e. weight-loss) pharmacological effect, ephedra is also susceptible to a variety of adulterants, both economic and efficacious. All of the foregoing represent potential for misadventure before ephedra even reaches the consumer. The consumer introduces a constellation of variables as well, including, but not limited to, acute and chronic diseases, inborn errors in metabolism, simultaneous use of prescription and over-the-counter drugs, dietary supplements, alcohol, illicit substances and certain foods (e.g. chocolate, caffeinated drinks), all or some of which may exert synergistic, additive or even antagonistic influences on the desired physiologic outcome. The foregoing not withstanding, the majority of the published nonclinical and clinical studies, and history of use, support the safety of ephedra at the proposed use levels. However, the reports of adverse events submitted to FDA raise concern about the risk associated with ephedra without establishing a direct causal relationship. Given the foregoing, how best can a decision on safety be made? Should the question actually be "can ephedra be as toxic as reported?"
authors.affiliation: Burdock Group, 780 US Highway 1, Suite 300, Vero Beach, FL 32962, USA. msoni@burdockgroup.com
authors.forename: Madhusudan G
authors.initials: MG
authors.lastname: Soni
authors.forename: Ioana G
authors.initials: IG
authors.lastname: Carabin
authors.forename: James C
authors.initials: JC
authors.lastname: Griffiths
authors.forename: George A
authors.initials: GA
authors.lastname: Burdock
mesh_terms: D018927:Anti-Asthmatic Agents / Q000627:therapeutic use; D002681:China; D029789:Ephedra / Q000009:adverse effects* / Q000633:toxicity; D004809:Ephedrine / Q000493:pharmacokinetics / Q000627:therapeutic use; D049690:History, Ancient; D006801:Humans; D008517:Phytotherapy / Q000266:history; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D018927:Anti-Asthmatic Agents; D004809:Ephedrine